Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03237065 · ClinicalTrials.gov registry record · Phase 3
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
A Phase 3 study, sponsored by Pharmacosmos A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
NCT03237065 is a Phase 3 study that has completed, run by Pharmacosmos A/S. The registered enrollment target is 122 participants.
The verdict
NCT03237065, a Phase 3 study, has completed, sponsored by Pharmacosmos A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
Study Summary
The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).
Interventions
- DRUG Ferric carboxymaltose
- DRUG Iron isomaltoside/ferric derisomaltose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2017-10-30 |
| Est. Completion | 2018-05-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03237065
The ClinicalTrials.gov registry entry for NCT03237065 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacosmos A/S, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferric carboxymaltose is the first listed.
NCT03237065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03237065 about?
NCT03237065 is a clinical study titled "Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia". The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).
What is the current status of trial NCT03237065?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2017-10-30. Estimated completion is 2018-05-29.
What interventions are being tested in trial NCT03237065?
The interventions under investigation include: Ferric carboxymaltose (DRUG), Iron isomaltoside/ferric derisomaltose (DRUG).
Who is sponsoring clinical trial NCT03237065?
This trial is sponsored by Pharmacosmos A/S, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.